Status:
COMPLETED
Adaptive Radiotherapy in Non-small Cell Lung Cancer (NSCLC)
Lead Sponsor:
Maastricht Radiation Oncology
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The investigators group uses an individualised radiation dose approach in which the dose is escalated up to pre-defined tissue constraints (see below). The target dose to the tumor is 69Gy. However, t...
Detailed Description
Eligible patients will receive concurrent chemo-radiotherapy to the primary tumor and the initially involved mediastinal lymph nodes to an MLD (Mean Lung Dose) of 20 +/- 1Gy, irrespective of lung func...
Eligibility Criteria
Inclusion
- Histological or cytological proven NSCLC
- UICC stage I-III, or solitary metastases (\<6), which are amendable for radical local treatment
- Performance status 0-2
- IMRT technique
Exclusion
- Not NSCLC of mixed NSCLC and other histologies (e.g. small cell carcinoma)
- Stage IV, except for solitary (\<6) metastases
- Performance status 3 or more
Key Trial Info
Start Date :
March 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2018
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01207063
Start Date
March 1 2011
End Date
August 1 2018
Last Update
August 17 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MAASTRO clinic
Maastricht, Limburg, Netherlands, 6229 ET